PD-L1 Expression Detection SP263 Assay for Immunotherapy Eligibility

Overview

PD-L1 protein measured by the SP263 assay predicts which patients may respond to immune checkpoint blockade. This testing service delivers a standardized SP263 result that regulatory labels recognize for several tumor types. Consistent staining and scoring protect the clinician from assay-to-assay inconsistency. Repeated scoring during treatment can track shifts in immune phenotype for selected cases.

How It Works

Slides bearing the tumor section are incubated with the SP263 antibody under controlled conditions. An automated stainer applies calibrated reagent volumes so membrane staining stays reproducible. Pathologists score the proportion of positive tumor cells using the approved percentage cut-offs. Internal controls confirm that reagent performance met the validated run specifications. Pre-analytical fixation time is governed because over-fixed tissue weakens membrane signal.

Indications

Non-small cell lung cancer cases are evaluated to decide eligibility for immunotherapy combinations. Urothelial and head-and-neck tumors use the same score to support checkpoint inhibitor selection. Esophageal tumors with overlapping histology are sometimes scored under this same method. Triple-negative breast cases may be tested when guideline pathways call for SP263 evidence. Small-cell lung cases are scored when a combined chemo-immune plan is under consideration.

Specimen Requirements & Reporting

Results return as a tumor proportion score with the validated threshold clearly stated. Reporting follows the assay's approved interpretation guide rather than local convention. Slides are retained per laboratory policy to enable advisory re-review. Decalcified bone specimens are accepted only when the process preserves antigen reactivity.

Storage & Sourcing

Unstained sections are stored in desiccated, temperature-stable conditions until processing. External laboratories may send blocks through tracked cold-chain courier service. Validation certificates are available to satisfy hospital procurement and audit needs. Reagent lot certificates are archived so every released slide traces to its validation record.

FAQ

Q: Is the SP263 assay validated as a companion diagnostic? A: The method follows the validated companion-diagnostic protocol, and certificates are available for payer and audit review.

Q: What is the reported scoring format for SP263? A: We report a tumor proportion score with the approved cut-off stated so eligibility is unambiguous.

Q: How is assay quality controlled in the laboratory? A: Automated staining, internal controls, and run-validation checks confirm reagent performance before release.

Q: Can SP263 results be contested or repeated? A: Retained slides allow advisory re-review, and repeat staining can be arranged under the laboratory retention policy.